SilicoGenesis

SilicoGenesis is a biotechnology startup headquartered in Belgium, founded in 2021. The company specializes in revolutionizing the field of antibody and biologic design, discovery, and optimization through its AI-enabled in silico antibody engineering platform. SilicoGenesis offers a comprehensive suite of solutions in the drug discovery pipeline, including precise 3D modeling of protein structures, accurate prediction of paratope and epitope residues, and thorough characterization and modeling of protein-protein interactions. The company's cutting-edge expertise and advanced technologies empower pharmaceutical and biotech companies to expedite and scale up the discovery and optimization of antibody lead molecules.

Having established a strong track record of successful collaborations with numerous pharmaceutical companies, biotech firms, and academic institutions, SilicoGenesis is emerging as a leader in the industry. The company's state-of-the-art AI/ML algorithms, in-silico pipelines, and collaborative expert team enable rapid development of innovative therapeutic lead molecules, while also offering services such as cross-species reactivity analysis, expert humanization of antibody candidates, and rigorous assessment of developability liabilities.

SilicoGenesis is committed to supporting specific needs and objectives in the biotechnology industry, with a focus on expediting and enhancing the drug discovery process. To learn more about their transformative capabilities, interested parties can visit their website at www.silicogenesis.com.